Corrigendum: (-)-epigallocatechin-3-gallate inhibits enos uncoupling and alleviates high glucose-induced dysfunction and apoptosis of human umbilical vein endothelial cells by pi3k/akt/enos pathway (Diabetes Metab Syndr Obes. 2020, 13 2495—2504.)

Z. Zhang; D. Zhang

ArticleOPEN ACCESS

Corrigendum: (-)-epigallocatechin-3-gallate inhibits enos uncoupling and alleviates high glucose-induced dysfunction and apoptosis of human umbilical vein endothelial cells by pi3k/akt/enos pathway (Diabetes Metab Syndr Obes. 2020, 13 2495—2504.)

Diabetes, Metabolic Syndrome and Obesity

DOI: 10.2147/DMSO.S274564

0Citations

10Readers

Abstract

It has come to the authors attention that the concentration of the used compound EGCG in Figures 1-5 is given in µm (micrometer) where it should be µM (micromolar). The figure legends are correct with µM. The authors apologize for this error in the figures.

Cite

CITATION STYLE

APA

Zhang, Z., & Zhang, D. (2020). Corrigendum: (-)-epigallocatechin-3-gallate inhibits enos uncoupling and alleviates high glucose-induced dysfunction and apoptosis of human umbilical vein endothelial cells by pi3k/akt/enos pathway (Diabetes Metab Syndr Obes. 2020, 13 2495—2504.). Diabetes, Metabolic Syndrome and Obesity. Dove Medical Press Ltd. https://doi.org/10.2147/DMSO.S274564

Corrigendum: (-)-epigallocatechin-3-gallate inhibits enos uncoupling and alleviates high glucose-induced dysfunction and apoptosis of human umbilical vein endothelial cells by pi3k/akt/enos pathway (Diabetes Metab Syndr Obes. 2020, 13 2495—2504.)

Abstract

Cite

Register to see more suggestions